The pharmacovigilance program on natalizumab in Italy: 2 years of experience


At the end of 2006 a country-based surveillance program on natalizumab therapy in multiple sclerosis was settled in Italy by a collaborative effort of the Italian Drug Agency (AIFA) and a group of experts and neurologists appointed by the National Society of Neurology (SIN). After 2 years, 1,818 patients are registered in the database. The majority of cases… (More)
DOI: 10.1007/s10072-009-0143-6


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.